1
Clinical Trials associated with CD34 selected T-cell depleted allogeneic SCT(New York Medical College)Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients.
Funding Source - FDA OOPD
100 Clinical Results associated with CD34 selected T-cell depleted allogeneic SCT(New York Medical College)
100 Translational Medicine associated with CD34 selected T-cell depleted allogeneic SCT(New York Medical College)
100 Patents (Medical) associated with CD34 selected T-cell depleted allogeneic SCT(New York Medical College)
100 Deals associated with CD34 selected T-cell depleted allogeneic SCT(New York Medical College)